KEBI-Cyto Study - Use of the Biocartis Idylla

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions
Pancreatic AdenocarcinomaLung Cancer
Interventions
DIAGNOSTIC_TEST

Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples

Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.

Trial Locations (1)

TR1 3LJ

Royal Cornwall Hospital, Truro

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biocartis NV

INDUSTRY

lead

Royal Cornwall Hospitals Trust

OTHER